Literature DB >> 33671422

Streptococcus pneumoniae and Its Virulence Factors H2O2 and Pneumolysin Are Potent Mediators of the Acute Chest Syndrome in Sickle Cell Disease.

Joyce Gonzales1, Trinad Chakraborty2, Maritza Romero3,4, Mobarak Abu Mraheil2, Abdullah Kutlar1, Betty Pace5, Rudolf Lucas1,3,4.   

Abstract

Sickle cell disease (SCD) is one of the most common autosomal recessive disorders in the world. Due to functional asplenia, a dysfunctional antibody response, antibiotic drug resistance and poor response to immunization, SCD patients have impaired immunity. A leading cause of hospitalization and death in SCD patients is the acute chest syndrome (ACS). This complication is especially manifested upon infection of SCD patients with Streptococcus pneumoniae (Spn)-a facultative anaerobic Gram-positive bacterium that causes lower respiratory tract infections. Spn has developed increased rates of antibiotics resistance and is particularly virulent in SCD patients. The primary defense against Spn is the generation of reactive oxygen species (ROS) during the oxidative burst of neutrophils and macrophages. Paradoxically, Spn itself produces high levels of the ROS hydrogen peroxide (H2O2) as a virulence strategy. Apart from H2O2, Spn also secretes another virulence factor, i.e., the pore-forming exotoxin pneumolysin (PLY), a potent mediator of lung injury in patients with pneumonia in general and particularly in those with SCD. PLY is released early on in infection either by autolysis or bacterial lysis following the treatment with antibiotics and has a broad range of biological activities. This review will discuss recent findings on the role of pneumococci in ACS pathogenesis and on strategies to counteract the devastating effects of its virulence factors on the lungs in SCD patients.

Entities:  

Keywords:  H2O2; Streptococcus pneumoniae; acute chest syndrome; pneumolysin; sickle cell disease

Mesh:

Substances:

Year:  2021        PMID: 33671422      PMCID: PMC7922783          DOI: 10.3390/toxins13020157

Source DB:  PubMed          Journal:  Toxins (Basel)        ISSN: 2072-6651            Impact factor:   4.546


  74 in total

Review 1.  Overwhelming post-splenectomy infection (OPSI): a case report and review of the literature.

Authors:  Trent L Morgan; Eric B Tomich
Journal:  J Emerg Med       Date:  2012-06-21       Impact factor: 1.484

Review 2.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

Review 3.  Pathogenesis, treatment, and prevention of pneumococcal pneumonia.

Authors:  Tom van der Poll; Steven M Opal
Journal:  Lancet       Date:  2009-10-31       Impact factor: 79.321

4.  CD36 mediates H2O2-induced calcium influx in lung microvascular endothelial cells.

Authors:  Karthik Suresh; Laura Servinsky; Jose Reyes; Clark Undem; Joel Zaldumbide; Otgonchimeg Rentsendorj; Sruti Modekurty; Jeffrey M Dodd-O; Alan Scott; David B Pearse; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-12-02       Impact factor: 5.464

5.  Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease.

Authors:  L A Styles; A J Aarsman; E P Vichinsky; F A Kuypers
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

6.  Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia.

Authors:  Martin Witzenrath; Birgitt Gutbier; Andreas C Hocke; Bernd Schmeck; Stefan Hippenstiel; Katharina Berger; Timothy J Mitchell; Juan R de los Toyos; Simone Rosseau; Norbert Suttorp; Hartwig Schütte
Journal:  Crit Care Med       Date:  2006-07       Impact factor: 7.598

7.  Induction of fetal hemoglobin synthesis by valproate: modulation of MAP kinase pathways.

Authors:  O Witt; S Mönkemeyer; K Kanbach; A Pekrun
Journal:  Am J Hematol       Date:  2002-09       Impact factor: 10.047

Review 8.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

9.  The role of pneumolysin in mediating lung damage in a lethal pneumococcal pneumonia murine model.

Authors:  María Del Mar García-Suárez; Noelia Flórez; Aurora Astudillo; Fernando Vázquez; Roberto Villaverde; Kevin Fabrizio; Liise-Anne Pirofski; Francisco J Méndez
Journal:  Respir Res       Date:  2007-01-26

Review 10.  Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs.

Authors:  Rudolf Lucas; Istvan Czikora; Supriya Sridhar; Evgeny Zemskov; Boris Gorshkov; Umapathy Siddaramappa; Aluya Oseghale; Jonathan Lawson; Alexander Verin; Ferenc G Rick; Norman L Block; Helena Pillich; Maritza Romero; Martin Leustik; Andrew V Schally; Trinad Chakraborty
Journal:  Toxins (Basel)       Date:  2013-07-15       Impact factor: 4.546

View more
  3 in total

1.  Core genes involved in the regulation of acute lung injury and their association with COVID-19 and tumor progression: A bioinformatics and experimental study.

Authors:  Aleksandra V Sen'kova; Innokenty A Savin; Evgenyi V Brenner; Marina A Zenkova; Andrey V Markov
Journal:  PLoS One       Date:  2021-11-22       Impact factor: 3.240

Review 2.  The Mycoplasma spp. 'Releasome': A New Concept for a Long-Known Phenomenon.

Authors:  Patrice Gaurivaud; Florence Tardy
Journal:  Front Microbiol       Date:  2022-04-15       Impact factor: 5.640

3.  Incidence of Acute Chest Syndrome in Children With Sickle Cell Disease Following Implementation of the 13-Valent Pneumococcal Conjugate Vaccine in France.

Authors:  Zein Assad; Morgane Michel; Zaba Valtuille; Andrea Lazzati; Priscilla Boizeau; Fouad Madhi; Jean Gaschignard; Luu-Ly Pham; Marion Caseris; Robert Cohen; Florentia Kaguelidou; Emmanuelle Varon; Corinne Alberti; Albert Faye; François Angoulvant; Bérengère Koehl; Naïm Ouldali
Journal:  JAMA Netw Open       Date:  2022-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.